1. 4. A Phase 1 Study of TSR-022 (Anti-TIM-3) in Combination with Dostarlimab (TSR-042, Anti-PD-1), 2. Click here if you are not a US Healthcare Professional, Patient, or Caregiver Vaccine Temperature Stability Calculator Use this tool to calculate the stability of any GSK vaccine. POSTER: Evaluation of an Individualized Starting Dose of Niraparib in the PRIMA/ENGOT-OV26/GOG-3012 Study, 4. POSTER: Discovery and characterization of the CD96 antibody GSK6097608, a high-affinity, antagonistic anti-CD96 antibody for cancer immunotherapy, 1. Prevnar 13 is stable at temperatures up to 25C (77F) for 4 days. Trends Cancer. Programmed cell death protein 1 (PD-1) is an immune checkpoint molecule that interacts with the PD-1 ligands PD-L1 and PD-L2 to limit T-cellmediated immune responses. Andrews LP, Marciscano AE, Drake CG, Vignali DAA. Review the package insert for important safety information. Baseline Characteristics in Patients with Eosinophilic Granulomatosis with Polyangiitis in the U.S. PUBLICATION ONLY: Real-world treatment patterns of patients initiating third-line therapy in relapsed or refractory multiple myeloma in Europe, 14. POSTER: Post-hoc analysis from two phase I/II NY-ESO-1-TCR T-cell therapy clinical trials in patients with advanced sarcoma (SS or MRCLS) demonstrates response across a range of NY-ESO-1 expression, 3. Montes de Oca R, Bhattacharya S, Vitali N, et al. 2015;7(11):1187-1199. Vaccine Stability Calculator Prevnar 13 Prevnar 20. 2. Singh AK, et al. Hemoglobin Efficacy and Cardiovascular Safety Data from the ASCEND-ND, -D, and -ID Trials. 1. ABSTRACT ONLY: Biomarker correlates of letetresgene autoleucel (lete-cel; GSK3377794) response in patients with advanced myxoid/round cell liposarcoma (MRCLS), 2. Safety and efficacy of dostarlimab in patients (pts) with recurrent/advanced non-small cell lung cancer (NSCLC), 8. Singh AK, et al. 1. Trademarks are owned by or licensed to the GSK group of companies. POSTER: Marijam A, et al. The site you are linking to is not controlled or endorsed by GSK and GSK is not responsible for its content. 11. DREAMM-7: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin (Belamaf) with Bortezomib, and Dexamethasone (B-Vd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM), 9. P742; Abstract A4771]. 1. Seasonal Efficacy of Mepolizumab in Patients With Severe Eosinophilic Asthma Meta-analysis From Two Phase 3 Trials. Based on rounding rules, temperatures between 1.5 C and 8.4 C (34.7 F-47.2 F) are within the recommended range for this vaccine. DREAMM-6: Safety and Tolerability of Belantamab Mafodotin in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM) [Poster not available for viewing due to copyright restrictions], 15. POSTER: Management of immune-related adverse events in patients with solid tumours treated with dostarlimab in the GARNET study (IGCS ENCORE), 1.POSTER: AGO-OVAR 28 / ENGOT-ov57: Niraparib vs niraparib in combination with bevacizumab in patients with carboplatin-taxane based chemotherapy in advanced ovarian cancer (A multicentre randomised phase III trial) (Presentation Posted With Permission), 2.POSTER: Characterization of long term survivor and maintenance therapy in relapsed ovarian cancer (CAROLIN)- Intergroup study NOGGO / A-AGO (Presentation Posted With Permission), 3.POSTER: Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician's choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33) (Presentation Posted With Permission), 1. POSTER: Meta-analysis of pazopanib and trabectedin in 2L+ metastatic synovial sarcoma (2L+ mSS), 5. POSTER: Antitumor activity of dostarlimab by PD-L1 and tumor mutation burden (TMB) in patients (pts) with mismatch repair deficient and proficient (dMMR and MMRp) tumors in the GARNET trial (AACR ENCORE), 9. Real-world adherence to single-inhaler versus multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in a commercially insured US population. POSTER: Progression-free survival (PFS) and overall survival (OS) in advanced/recurrent (AR) mismatch repair deficient/microsatellite instabilityhigh or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC) treated with dostarlimab in the GARNET study, 5. Economic and Humanistic Outcomes Associated with Treatment of Recurrent or Metastatic Cervical Cancer: A Literature Review. Hemoglobin Efficacy and Cardiovascular Safety Data from the ASCEND-ND, -D, and -ID Trials. Healthcare Resource Utilization and Costs Associated with COVID-19 Among Hospitalized Patients in the United States A Population Study. Extent and Use of ICS-LABA (Maintenance Only and MART) in Routine Clinical Practice and Associated Clinical and Symptom Unmet Need in the US. Slade D, Ray R, Moretz C, et al. LAG3 (CD223) as a cancer immunotherapy target. 4. National Differences in Real-World Outcomes with Mepolizumab Treatment for Patients with Severe Asthma: Results from the REALITI-A Study. PUBLICATION ONLY: Treatment Patterns of Advanced or Recurrent Endometrial Cancer Following Platinum-Based Therapy in the US Real-World Setting, 23. Patient Experience of Physician-Patient Communication and Delayed or Misdiagnosis in Patients With Eosinophil-Driven Diseases. 3. 5. PRMT5 is overexpressed in multiple tumor types, including lymphoma and breast, lung, and bladder cancer, and regulates splicing, gene expression, and activation of p53. Matching-Adjusted Indirect Comparisons (MAIC) of Safety Between Single-Agent Belantamab Mafodotin Versus Selinexor Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM), 9. Impact of State Residence on Adult Vaccination Uptake: A Multilevel Modeling Approach. Obrador GT, et al. ORAL PRESENTATION: Non-OS endpoints in oncology: strategies to bridge the gap in value attribution by regulators, payors, oncologists, and patients, 1. Ferguson GT, Brown N, Compton C, et al. Real-World Benefits of Mepolizumab in Patients With Overlapping Allergic and Eosinophilic Endophenotypes: Post Hoc Analysis of REALITI-A by Omalizumab Eligibility, Real-World Benefits of Mepolizumab in Patients With Severe Asthma and Comorbid GERD or Anxiety/Depression: Post Hoc Analysis of REALITI-A, Change in nasal polyp size as an indicator of treatment response: SYNAPSE trial analysis, Patient Profiles in Eosinophilic Granulomatosis With Polyangiitis (EGPA) Insights From Allergy Practice. Benefits of Initiating Single-Inhaler Triple Therapy (SITT) with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Multiple-Inhaler Triple Therapy (MITT) Among Medicare Advantage with Part D Beneficiaries with Chronic Obstructive Pulmonary Disease (COPD). Patient-Reported Experiences During and Following Treatment with Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM) in the DREAMM-2 Study, 3. Daprodustat is not associated with an increased risk of cancer: results from the ASCEND-D and ASCEND-ND trials. Upon receipt, store refrigerated at 2C to 8C (36F to 46F). Lu E, et al. Zhang S, White J, Meeraus W, et al. Healthcare Resource Utilization and Costs Associated with COVID-19 Among Hospitalized Patients in the United States A Population Study. Healthcare Resource Utilization and Costs Over 5 Years for a Systemic Lupus Erythematosus Cohort Newly Diagnosed With Lupus Nephritis: Evidence From a US Administrative Claims Database. NY-ESO-1specific TCRengineered T cells mediate sustained antigen-specific antitumor effects in myeloma. ORAL PRESENTATION: Kohli A, et al. Abstract Publication No. POSTER: Transfusion Independence Response As a Potential Surrogate for Overall Survival in Jaki-Experienced Patients with Myelofibrosis from Momentum, 7. Baseline Characteristics in Patients with Eosinophilic Granulomatosis with Polyangiitis in the U.S. Strobel MJ, Alves D, Roufosse F, et al. Poster No. Silver J, Deb A, Packnett E, et al Disclaimer: For vaccines that require reconstitution before administration, the stability data here applies only to storage prior to reconstitution. ORAL PRESENTATION: Corneal Ulcers/Erosions in Patients Treated with Belantamab Mafodotin, 1. The Potential for Reducing Opioid and Analgesic Prescriptions via Herpes Zoster Vaccination, 8. 6. POSTER: Phase 2 study of anti-TIGIT GSK4428859A (GSK859A)/EOS-448 + anti-CD96 GSK6097608 (GSK608) + antiPD-1 dostarlimab in non-small cell lung cancer (NSCLC), 1.POSTER: Prevalence and clinical characteristics of metastatic synovial sarcoma (mSS) patients with tumours expressing NY-ESO-1 antigen (NY+) and who are HLA-A*02:01, *02:05 or *02:06 allele positive (HLA+): Cohort study from the French Sarcoma Group (Presentation Posted With Permission), 1.POSTER: NIRVANA-1: A multicentric randomized trial to compare carboplatin-paclitaxel (CP) followed by niraparib (nira) to CPbevacizumab (bev) followed by nira-bev in patients with stage IIIA/B/C high-grade epithelial ovarian cancer with no residual disease after frontline surgery (Presentation Posted With Permission), 1. A Prospective Evaluation of Tolerability of Niraparib Dosing Based Upon Baseline Body Weight and Platelet Count: Blinded Pooled Interim Safety Data From the PRIMA/ENGOT OV26/GOG 3012 Study, 3. Smith SG, Price R, Mollo MR, et al. Temperature Excursion Worksheet . Views of US pulmonologists on the prevalence of uncontrolled asthma, treatment decisions and the role of treatable traits: results from the CHEST Pulse Surveys. 4. CAPTAIN: Effects of age as a continuous variable on asthma control. Dasgupta, I et al. Non-clinical tumor models reveal broad combination potential of ICOS agonist antibodies, April 10-15, 2021 and May 17-21, 2021 | Virtual, 1. 2. Use of Mepolizumab among Individuals with Asthma in the U.S. [Poster No. Once-daily, single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus FF/VI in inadequately controlled asthma: the CAPTAIN study, 1. AGSK Stability Calculator GlaxoSmithKline (GSK) 888-825-5249 Sano Pasteur 800-822-2463 Sequiris 855-358-8966 ZEJULA [package insert]. The Sustained OCS-Sparing Effect of Mepolizumab: Results From the Real-World REALITI-A Study at 2 Years. 11. Analysis of a Composite Endpoint of Exacerbation and Early Study Treatment Withdrawal in Symptomatic Patients With COPD Free of Inhaled Corticosteroids: A Post Hoc Analysis of the EMAX Trial. Obrador GT, et al. Temperature Excursion Worksheet . Seo J, Zhang S, Zhang D, et al. [Poster No. If your vaccine was exposed to above recommended temperature, please call us at 1-877-GSK-MI4U (1-877-475-6448). Effect of Serostatus on the Efficacy of Sotrovimab in Preventing COVID-19 Progression, 2. Poster No. Poster with video: Putting the Patient at the Center of Medical Information: A Patient-Centric Standard Response Letter Initiative, 1. 7. Sanofi Pasteur 800-822-2463 . Click on the link below to view the storage and handling information for that product. Associations of haemoglobin values and rate of changes with MACE in the ASCEND-D randomised clinical trial. POSTER: Single-agent Belantamab Mafodotin in Patients With Relapsed or Refractory Multiple Myeloma: Final Analysis of the DREAMM-2 trial, 2. Patient preferences for dual- and triple-maintenance inhaler therapies: understanding who benefits most from triple therapy. ORAL PRESENTATION: Impact of baseline ocular conditions (BOCs) on belantamab mafodotin (belamaf)-related corneal events in patients (pts) with relapsed or refractory multiple myeloma (RRMM), 1. By clicking this link, you will be taken to a website that is independent from GSK. Rothnie K, Han X, Bancroft T, et al. POSTER: RSVPreF3 OA Candidate Vaccine Efficacy Presentation. (Poster No. 3. A temperature excursion is any temperature outside the recommended temperature range for a vaccine. Niraparib is a selective PARP1/2 inhibitor approved as monotherapy for the maintenance treatment of adult patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy. Preclinical evaluation of a non-depleting, first-in-class humanized IgG4 agonist anti-ICOS antibody, 2. Analysis of Co-Resistance Among Escherichia coli Urine Isolates From Female Outpatients in the United States. Safety of Belimumab in Adult Patients With Systemic Lupus Erythematosus: A Large Integrated Safety Analysis of Controlled Clinical Trial Data, 1. Encore: Open-label Pilot Study of Genetically Engineered NY-ESO-1Specific T Cells (GSK3377794) Alone or in Combination With Pembrolizumab in Relapsed/Refractory Multiple Myeloma [Publication only], Pilot Neoadjuvant Study of Niraparib in HER2-Negative, BRCA-Mutated Resectable Breast Cancer, 1. 61), 1. DREAMM-4: Evaluating Safety and Clinical Activity of Belantamab Mafodotin in Combination With Pembrolizumab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) [Poster not available for viewing due to copyright restrictions], 14. PO0465, 4. Modeling of short-acting beta agonist (SABA) use: effect of symptom control in patients with moderate-severe asthma requiring rescue medication. Efficacy of Mepolizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis and a Vasculitic Phenotype. Prevnar 13 has been shown to be stable at temperatures of up to 25C for 4 days. JASPER: Efficacy and Safety of First-Line (1L) Niraparib Plus a Programmed Death Receptor-1 Inhibitor (PD-1i) in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC), 6. POSTER: VOCAL (Views of Ovarian Cancer patients-how maintenance therapy Affects their Lives) study: patient preference for treatment formulation and administration (IGCS 2022), 2. 4. Associations between haemoglobin values and rate of changes with MACE in the ASCEND-ND randomised clinical trial. Infusion-Related Reactions (IRRs) in the DREAMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM), 5. Bell CF, et al. 1. Prazma C, Bernstein D, Brightling C, et al. Characterization of severe asthma patients affiliated to the Hospital Italiano Medical Care Program in Buenos Aires, Argentina. Real-World Safety and Effectiveness of Fluticasone Furoate/Vilanterol in Patients with Asthma or Chronic Obstructive Pulmonary Disease: A Post-Marketing Study in Korea. This medical information is intended only for healthcare professionals registered to practice in the United States and is intended to provide balanced, scientific, and evidence-based answers to unsolicited medical questions. Tabberer M, von Maltzahn R, Bacci E, et al. Patient Perceptions of Treatment Success in Uncomplicated Urinary Tract Infection. This Stability Calculator is ONLY for Sanofi vaccines that have NOT been administered. Patient-reported outcomes (PRO) in patients receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial ESMO 2020, 2. Wu AC, McMahon PM, Mendelsohn A, et al. POSTER: Efficacy of dostarlimab in endometrial cancer by molecular subtype: a post hoc analysis of the GARNET study (ESMO ENCORE), 10. CAPTAIN Study: Association of moderate and severe asthma exacerbations with lung function and patient-reported outcomes in a large randomized phase III clinical trial. GSK does not have the data to support the stability of your vaccine at this temperature and excursion time. Targeting B-cell maturation antigen in multiple myeloma. Cumulative multiple temperature excursions between 8C and 25C are permitted, as long as the total time does not exceed 4 days (96 hours). CAPTAIN Study: Simultaneous Step-up to High Dose Fluticasone Furoate and Addition of Umeclidinium for the Treatment of Inadequately Controlled Asthma. Bell CF, et al. Oral presentation. [Poster No. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Impact of the COVID-19 Pandemic on Health Care Resource Utilization (HCRU) and Costs in Asthma in the United States: A Population-Based Study. Simply select from the required information below. GSK3326595, a selective inhibitor of PRMT5, is being investigated as a monotherapy in solid tumors and in combination with other therapies in various hematologic malignancies. 7. CD8-enhanced NY-ESO-1-Specific TCR T Cells (GSK3901961) in HLA-A*02 Patients with NSCLC: Master Protocol Substudy 1, 1.ORAL PRESENTATION:DREAMM-6: Safety and Tolerability of Belantamab Mafodotin in Combination with Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM). 6. Pivotal DREAMM-2 Study: Single-Agent Belantamab Mafodotin (Belamaf; GSK2857916) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to Proteasome Inhibitors, Immunomodulatory Agents, and Refractory and/or Intolerant to Anti-CD38 Monoclonal Antibodies (mAbs), Including Subgroups with Renal Impairment (RI) and High-Risk (HR) Cytogenetics, 3. Preliminary Safety, Efficacy, and PK/PD Characterization from GARNET, a Phase 1 Clinical Trial of the Anti-PD-1 Monoclonal Antibody, TSR-052, in Patients with Recurrent or Advanced MSI-H Endometrial Cancer, A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight and platelet count: blinded pooled interim safety data from the PRIMA/ENGOT-OV26/GOGO3012 Study, Preliminary safety, efficacy, and PK/PD characterization from GARNET, a phase 1 clinical trial of the Anti-PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced MSI-H endometrial cancer, 1. Epidemiology of Eosinophilic Granulomatosis with Polyangiitis (EGPA) and Hypereosinophilic Syndrome (HES) in Germany: A Claims Database Study. [Poster No. [Poster No. P276; Abstract A4811]. The anti-tumor efficacy of TIM-3 blockade in a murine model of sarcoma, 1. The Severe Asthma Patient Experience: In-Clinic and Self-Administration of Mepolizumab. 6. 1. Elaborating the Mechanism of PARP Synthetic Lethality in ATM Loss, 2. POSTER: A report of the postmarketing spontaneous safety data over 24 years for GSKs measles-mumps-rubella (MMR) vaccine. Poster with video: Safety and patient-reported outcomes in patients receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial, 2. [Poster No. Poster No. Erythropoiesis-Stimulating Agent Hyporesponsiveness and Anemia Management in the ASCEND-D Trial, 6. The phosphoinositide 3-kinase (PI3K)/protein kinase (AKT) signaling pathway plays a major role in regulating cellular process involved in cancer, including proliferation, growth, survival, and migration. Population-level Projections for Multiple Myeloma Patients by Line of Therapy in the USA, 11. Efficacy and Safety of Mepolizumab in Hypereosinophilic Syndrome: a Phase III, Randomized, Placebo-Controlled Trial. POSTER: Factors Affecting PARP Inhibitor Use as Maintenance Treatment in Platinum-Sensitive Recurrent Ovarian Cancer, 2. Bogart M, Wu B, Germain G, et al. Assessment of Asthma Control in Respiratory Specialist Offices in the US. 2. Poster No. Niraparib is being investigated as a monotherapy and in combination with other anticancer agents, including dostarlimab, in breast cancer, ovarian cancer, and advanced NSCLC. Real-World Benefits of Mepolizumab in Patients With Severe Asthma and Comorbid GERD or Anxiety/Depression: Post Hoc Analysis of REALITI-A (Poster No. Obeid D, Bansal S, Brown N, et al. Real-World Impact of Triple Therapy with Fluticasone Furoate, Umeclidinium, and Vilanterol on Asthma Control among Patients with Asthma in the US. GARNET: Preliminary Safety, Efficacy, Pharmacokinetic, and Biomarker Characterization from a Phase 1 Clinical Trial of TSR-042 (Anti-PD-1 Monoclonal Antibody) in Patients with Recurrent/Advanced NSCLC, 4. Encore: DREAMM-2: Single-Agent Belantamab Mafodotin in Relapsed/Refractory Multiple Myeloma Refractory to Proteasome Inhibitors, Immunomodulatory Agents, and Refractory and/or Intolerant to Anti-CD38 mAbs [Poster not available for viewing due to copyright restrictions], 7. Ismaila A, Haeussler K, Czira A, et al. 1. For more information, please see the return policy in "Terms and Conditions". 12. 7. B-cell maturation antigen (BCMA), a membrane protein expressed on malignant plasma cells in all patients with multiple myeloma, supports myeloma cell proliferation and survival. POSTER: Efficacy of dostarlimab in endometrial cancer (EC) by molecular subtype: A post hoc analysis of the GARNET study, 6. Stark A-K, Sriskantharjah S, Hessel EM, Okkenhaug K. PI3K inhibitors in inflammation, autoimmunity and cancer. Benefits of Initiating Single-Inhaler Triple Therapy (SITT) with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Multiple-Inhaler Triple Therapy (MITT) Among Medicare Advantage with Part D Beneficiaries with Chronic Obstructive Pulmonary Disease (COPD). Affairs portal to a separate website maintained by 2017;31(2):101-126. Changes in Oral Corticosteroid (OCS) Use Following Initiation of Mepolizumab Therapy in Patients with Asthma. Neutrophil extracellular traps and CXCR2 antagonism in chronic obstructive pulmonary disease: A pilot randomized control study. PUBLICATION ONLY: Quality Assurance in Ovarian Cancer (QS-OVAR), 15. Corbridge T, Casale T, Germain G, et al. Sustained Clinical Benefits in Patients With Chronic Rhinosinusitis With Nasal Polyps 24 Weeks Post-mepolizumab Treatment. (Poster No. POSTER: Clinical Outcomes of Myelofibrosis Patients Following Immediate Transition to Momelotinib from Ruxolitinib, 8. POSTER: AMBER Parts 1C and 1E: a Phase 1 Study of Cobolimab plus Dostarlimab in Patients with Advanced/Metastatic Melanoma, 13. Electronic address: didier.clenet@sanofi.com. On-Treatment Cancer Safety Events with Daprodustat Versus Erythropoiesis-Stimulating Agents Post hoc Analyses of ASCEND-ND and ASCEND-D, 1. P474; Abstract A3997]. Dransfield MT, Halpin DMG, Han MK, et al.